Clinical trial
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With…
NCT00110214 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00110214 |
|---|---|
| Title | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy |
| Official title | A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Doctaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) in Men With Hormone Refractory Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | docetaxel, placebo, prednisone, bevacizumab, laboratory biomarker analysis |
| Enrollment | 1,050 |
| Start date | Apr 1, 2005 |
| Primary completion | Mar 1, 2010 |
| Completion | Aug 1, 2011 |
| First posted | May 5, 2005 |
| Last update posted | May 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: